Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01549886 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01549886 is a Phase 2 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT01549886, a Phase 2 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the efficacy and safety of the Zevalin regimen compared to Zevalin and motexafin gadolinium in patients with rituximab-refractory, low-grade or follicular Non-Hodgkin's Lymphoma (NHL). Effectiveness of the experimental regimen assessed by complete response rate within 6 months of study entry (primary endpoint), complete response rate within 3 months of study entry, and overall response rate within 6 month of study entry.
Interventions
- DRUG Rituximab
- DRUG Y-90-Zevalin
- DRUG Moxtezafin Gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01549886
The ClinicalTrials.gov registry entry for NCT01549886 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT01549886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01549886 about?
NCT01549886 is a clinical study titled "Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma". The objectives of this study are to evaluate the efficacy and safety of the Zevalin regimen compared to Zevalin and motexafin gadolinium in patients with rituximab-refractory, low-grade or follicular Non-Hodgkin's Lymphoma (NHL). Effectiveness of the experimental regimen assessed by complete respon...
What is the current status of trial NCT01549886?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01549886?
The interventions under investigation include: Rituximab (DRUG), Y-90-Zevalin (DRUG), Moxtezafin Gadolinium (DRUG).
Who is sponsoring clinical trial NCT01549886?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.